Introduction: Clindamycin is commonly used to treat skin and soft tissue infections caused by Staphylococcus aureus particularly in methicillin-resistant S. aureus (MRSA) infections. Inducible clindamycin resistance (inducible macrolide–lincosamide–streptogramin B resistance [MLSB]) is a critical factor in antimicrobial susceptibility testing. This study was aimed to detect MLSB phenotypes and inducible clindamycin resistant phenotypes among S. aureus. Materials and Methods: A total of 649 S. aureus isolates from different clinical samples were evaluated, and methicillin-resistance was determined using the cefoxitin (30 μg) disc. Inducible resistance to clindamycin was detected by D-zone test as per Clinical and Laboratory Standards Institute guidelines. Results: Of the 649 isolates, 404 (62.2%) were methicillin-sensitive S. aureus (MSSA) and 245 (37.8%) were MRSA. Ninety-six (14.8%) isolates showed inducible clindamycin resistance, 175 (27%) showed constitutive resistance, and 55 (8.5%) isolates showed MS phenotype. Inducible and constitutive resistance phenotypes were found to be higher in MRSA (25% and 64.8%) as compared to MSSA (8.7% and 4.7%), respectively. Conclusions: Considering the higher prevalence of clindamycin resistance in MRSA isolates as compared MSSA isolates, routine D-test of MRSA isolates is strongly recommended to prevent treatment failure. Therefore, inducible clindamycin detection should be the part of S. aureus sensitivity testing in all the microbiology laboratories.